Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

13-12-2017 | Image

Figure 1. Timeline of US (bottom) and European (top) approvals of biosimilar agents for the treatment of rheumatological conditions to date.

Figure 1. Timeline of US (bottom) and European (top) approvals of biosimilar agents for the treatment of rheumatological conditions to date.

Details of indications are given in table 2.

print
PRINT
Image Credits